A Phase I Study of Bevacizumab (B) in Combination with Everolimus (E) and Erlotinib (E) in Advanced Cancer (BEE)

PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus and erlotinib combination. METHODS: Doublet therapy consisted of...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Bullock, Karen E., Petros, William P., Younis, Islam, Uronis, Hope E., Morse, Michael A., Blobe, Gerard C., Zafar, S. Yousuf, Gockerman, Jon P., Lager, Joanne J., Truax, Roxanne, Meadows, Kellen L., Howard, Leigh A., O’Neill, Margot M., Broadwater, Gloria, Hurwitz, Herbert I., Bendell, Johanna C.
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086252/
https://ncbi.nlm.nih.gov/pubmed/21079958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1507-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы